InvestorsHub Logo
icon url

BERKSHIRE AGENT

12/31/20 8:09 AM

#104535 RE: joh64 #104534

Wow we hit the MOTHERLODE with this one! REAL DEAL!

"As we round out 2020, we have significantly expanded our Intellectual Property portfolio based on many years of collaborative research and development. Utilizing the ImmCelz® technology for the treatment of heart failure is an excellent addition to this robust patent portfolio as it effects millions of patients in the U.S. alone. Patients with end stage heart failure in many cases have no options but heart transplantation, which is extremely limited." Said Timothy Warbington, President and CEO of the Company. "We are excited with the progress that the Company is making in advancing ImmCelz®, which approaches regenerative medicine from a completely unique perspective. Given that the active cells in ImmCelz® are derived from the same patient, we anticipate an accelerated path to FDA Investigational New Drug (IND) clearance."

"We encourage industry colleagues and other interested parties to review our early priority date patent filings to learn more about the ImmCelz® technology and how it applies to multiple indications" Mr. Warbington further said